PTJ
DSGN icon

Paul Tudor Jones’s Design Therapeutics DSGN Stock Holding History

Paul Tudor Jones’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18,738
Closed -$101K – 3123
2024
Q3 		$101K Sell
18,738
-1,127
-6% -$5.3K ﹤0.01% 2596
2024
Q2 		$66.5K Sell
19,865
-5,462
-22% -$21.3K ﹤0.01% 2220
2024
Q1 		$102K Buy
+25,327
New +$67.6K ﹤0.01% 2093
2023
Q4 		– Sell
-16,299
Closed -$38.5K – 2472
2023
Q3 		$38.5K Sell
16,299
-4,262
-21% -$19.9K ﹤0.01% 2192
2023
Q2 		$130K Sell
20,561
-7,078
-26% -$43.3K ﹤0.01% 2280
2023
Q1 		$159K Buy
27,639
+9,955
+56% +$74.5K ﹤0.01% 2209
2022
Q4 		$181K Sell
17,684
-10,182
-37% -$138K ﹤0.01% 2152
2022
Q3 		$466K Buy
27,866
+14,966
+116% +$298K 0.01% 1453
2022
Q2 		$181K Buy
+12,900
New +$174K ﹤0.01% 1850

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Paul Tudor Jones's DSGN Position: Q4 2024 in Review

Paul Tudor Jones sold out of Design Therapeutics (DSGN) in Q4 2024, closing a stake of 18,738 shares — an estimated $101K sold.

Paul Tudor Jones first reported a position in DSGN in Q2 2022 and held it in 9 quarters. The position peaked at $466K in Q3 2022. 95 funds tracked by Wall St. Rank hold DSGN as of Q4 2024.

  • Paul Tudor Jones reported no remaining Design Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Paul Tudor Jones sold 18,738 Design Therapeutics shares in Q4 2024, an estimated $101K.
  • Paul Tudor Jones first reported a position in Design Therapeutics in Q2 2022 and held it in 9 quarters.
  • Paul Tudor Jones's Design Therapeutics position peaked at $466K in Q3 2022.
  • 95 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2024.

Based on Tudor Investment Corp's 13F filing for Q4 2024, filed 14 Feb 2025.